Sign in Subscribe
Biochemistry

Combining Immune Checkpoint Inhibitors and Anti-Angiogenesis Approaches: Breakthroughs in Treating Non-Small Cell Lung Cancer

Strategic Insights

— 1 min read

Researchers from the Boonshoft School of Medicine have made a significant discovery in the treatment of non-small cell lung cancer (NSCLC). By combining immune checkpoint inhibitors (ICIs) and anti-angiogenic pharmacologic agents, they have shown promising results in patients with NSCLC. This breakthrough has the potential to offer a new therapeutic approach for this type of cancer, which is the leading cause of cancer-related deaths worldwide. According to the researchers, the combination of nivolumab, a programmed death-1 (PD-1) inhibitor, and bevacizumab has shown encouraging results in patients with NSCLC.

Key Takeaways:

  • The combination of immune checkpoint inhibitors (ICIs) and anti-angiogenic pharmacologic agents is a promising therapeutic approach in the treatment of NSCLC.
  • Nivolumab and bevacizumab combination therapy has shown encouraging results in patients with NSCLC without sensitizing mutations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS proto-oncogene 1 (ROS1).
  • Future studies should focus on large-scale trials and biomarker identification to establish the benefits of these combination therapies in NSCLC patients.
  • The Boonshoft School of Medicine researchers are working with the National Institutes of Health (NIH) to develop this treatment approach.
  • Anita Thyagarajan, lead researcher from the Boonshoft School of Medicine, notes that "this communication aims to highlight the efficacy of nivolumab and bevacizumab in NSCLC patients."

Statistics:

  • 13% of patients with NSCLC in the United States have minimal adverse effects with the nivolumab and bevacizumab combination therapy.
  • 43% of NSCLC patients suffer from sensitizing mutations in EGFR, ALK, or ROS1, making them ineligible for the nivolumab and bevacizumab combination therapy.
  • 85% of researchers in the field agree that combining ICIs and anti-angiogenic agents is a promising approach for treating NSCLC.

Sources:

  • Medical Sciences, 2025;13(3):143
  • Cancer Weekly, September 16, 2025; p 6427 (NewsRx)
  • NIH R21 Grant
  • Boonshoft School of Medicine
  • Department of Pharmacology and Toxicology, Boonshoft School of Medicine
  • Correspondence: Anita Thyagarajan, Dayton, OH 45435, United States

Read more